JP2015502340A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015502340A5 JP2015502340A5 JP2014539044A JP2014539044A JP2015502340A5 JP 2015502340 A5 JP2015502340 A5 JP 2015502340A5 JP 2014539044 A JP2014539044 A JP 2014539044A JP 2014539044 A JP2014539044 A JP 2014539044A JP 2015502340 A5 JP2015502340 A5 JP 2015502340A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- antibody
- variable region
- chain variable
- subject
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 210000000581 natural killer T-cell Anatomy 0.000 claims 7
- 206010020751 Hypersensitivity Diseases 0.000 claims 4
- 208000026935 allergic disease Diseases 0.000 claims 4
- 208000006673 asthma Diseases 0.000 claims 4
- 102000004127 Cytokines Human genes 0.000 claims 3
- 108090000695 Cytokines Proteins 0.000 claims 3
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims 3
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 claims 3
- 239000004473 Threonine Substances 0.000 claims 3
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 claims 3
- 230000003213 activating effect Effects 0.000 claims 3
- 230000000779 depleting effect Effects 0.000 claims 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
- 125000001909 leucine group Chemical group [H]N(*)C(C(*)=O)C([H])([H])C(C([H])([H])[H])C([H])([H])[H] 0.000 claims 3
- 210000002966 serum Anatomy 0.000 claims 3
- 208000024891 symptom Diseases 0.000 claims 3
- 125000000341 threoninyl group Chemical group [H]OC([H])(C([H])([H])[H])C([H])(N([H])[H])C(*)=O 0.000 claims 3
- 239000004474 valine Substances 0.000 claims 3
- 125000002987 valine group Chemical group [H]N([H])C([H])(C(*)=O)C([H])(C([H])([H])[H])C([H])([H])[H] 0.000 claims 3
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 2
- 230000007815 allergy Effects 0.000 claims 2
- 239000000427 antigen Substances 0.000 claims 2
- 102000036639 antigens Human genes 0.000 claims 2
- 108091007433 antigens Proteins 0.000 claims 2
- 230000000903 blocking effect Effects 0.000 claims 2
- 208000035475 disorder Diseases 0.000 claims 2
- 230000009610 hypersensitivity Effects 0.000 claims 2
- 230000028993 immune response Effects 0.000 claims 2
- 208000023275 Autoimmune disease Diseases 0.000 claims 1
- 208000035473 Communicable disease Diseases 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 206010063837 Reperfusion injury Diseases 0.000 claims 1
- 239000013566 allergen Substances 0.000 claims 1
- 201000009961 allergic asthma Diseases 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 230000003915 cell function Effects 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 claims 1
- 230000004968 inflammatory condition Effects 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 208000012947 ischemia reperfusion injury Diseases 0.000 claims 1
- 208000007056 sickle cell anemia Diseases 0.000 claims 1
- 238000002054 transplantation Methods 0.000 claims 1
- 230000003156 vasculitic effect Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161552337P | 2011-10-27 | 2011-10-27 | |
| US61/552,337 | 2011-10-27 | ||
| PCT/US2012/062124 WO2013063395A1 (en) | 2011-10-27 | 2012-10-26 | Humanized antibodies to inkt |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2015502340A JP2015502340A (ja) | 2015-01-22 |
| JP2015502340A5 true JP2015502340A5 (enExample) | 2015-12-17 |
Family
ID=48168549
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014539044A Pending JP2015502340A (ja) | 2011-10-27 | 2012-10-26 | ｉＮＫＴに対するヒト化抗体 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US9932402B2 (enExample) |
| EP (1) | EP2755688A4 (enExample) |
| JP (1) | JP2015502340A (enExample) |
| KR (1) | KR20140093964A (enExample) |
| CN (1) | CN103945867B (enExample) |
| AU (1) | AU2012328588C1 (enExample) |
| BR (1) | BR112014009962A2 (enExample) |
| CA (1) | CA2853719A1 (enExample) |
| HK (2) | HK1199405A1 (enExample) |
| IL (1) | IL232017A0 (enExample) |
| RU (1) | RU2014120694A (enExample) |
| SG (1) | SG11201401319XA (enExample) |
| WO (1) | WO2013063395A1 (enExample) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20140271629A1 (en) * | 2013-03-14 | 2014-09-18 | Amgen Inc. | Chrdl-1 antigen binding proteins and methods of treatment |
| WO2015069697A2 (en) * | 2013-11-05 | 2015-05-14 | Nkt Therapeutics Inc. | Combination therapy |
| AU2015204674B2 (en) * | 2014-01-10 | 2020-09-03 | Anaptysbio, Inc. | Antibodies directed against interleukin-33 (IL-33) |
| EP3104864A1 (en) * | 2014-02-14 | 2016-12-21 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions for the treatment of acute exacerbations of chronic obstructive pulmonary disease |
| TW202136296A (zh) * | 2014-06-27 | 2021-10-01 | 美商Ｃ２Ｎ醫療診斷有限責任公司 | 人類化抗-tau抗體 |
| EP3190415B1 (en) * | 2014-07-25 | 2019-05-01 | Riken | Memory invariant nkt cell marker |
| US20160022777A1 (en) * | 2014-07-28 | 2016-01-28 | Nkt Therapeutics Inc. | Combination therapy with il-12 |
| US11933786B2 (en) | 2015-03-30 | 2024-03-19 | Stcube, Inc. | Antibodies specific to glycosylated PD-L1 and methods of use thereof |
| EP3383412A4 (en) | 2015-12-02 | 2019-06-05 | Stcube, Inc. | SPECIFIC ANTIBODIES TO GLYCOSED PD-1 AND METHOD OF USE THEREOF |
| KR20180130541A (ko) | 2016-03-29 | 2018-12-07 | 주식회사 에스티큐브앤컴퍼니 | 글리코실화된 면역체크포인트 단백질에 특이적으로 결합하는 항체를 선택하는 방법 |
| WO2017176651A1 (en) | 2016-04-04 | 2017-10-12 | True North Therapeutics, Inc. | Anti-complement factor bb antibodies and uses thereof |
| CN109715666B (zh) | 2016-07-20 | 2023-02-21 | 斯特库比股份有限公司 | 癌症治疗方法和使用结合糖基化pd-l1的抗体的组合的疗法 |
| CN109923126B (zh) * | 2016-09-16 | 2022-06-03 | 上海复宏汉霖生物技术股份有限公司 | 抗-pd-1抗体 |
| CN113508137B (zh) * | 2019-01-29 | 2024-12-20 | 上海交通大学 | 一种嵌合抗原受体及其应用 |
| CA3173325A1 (en) * | 2020-04-20 | 2021-10-28 | Graham Parry | Humanized anti-complement factor bb antibodies and uses thereof |
| JP2023522979A (ja) * | 2020-04-23 | 2023-06-01 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | ｉＮＫＴ細胞の活性化による老化細胞の排除 |
| WO2022187141A1 (en) | 2021-03-01 | 2022-09-09 | Deciduous Therapeutics | Compounds for activating invariant natural killer t-cells and methods of use in eliminating inflammatory senescent cells |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7119248B1 (en) | 1994-04-12 | 2006-10-10 | Miltenyi Biotec Gmbh | Antibodies against epitopes with homology to self antigens, methods of preparation and applications thereof |
| AU7482696A (en) | 1995-11-01 | 1997-05-22 | Genetics Institute Inc. | Methods for administration of il-12 |
| WO1999034209A1 (en) | 1997-12-31 | 1999-07-08 | The Brigham And Women's Hospital, Inc. | DIAGNOSTIC AND THERAPEUTIC METHODS BASED UPON Vα24JαQ T CELLS |
| ES2389645T3 (es) | 2000-06-19 | 2012-10-30 | Beth Israel Deaconess Medical Center | Composiciones y métodos de anticuerpos monoclonales y policlonales específicos para subpoblaciones de linfocitos T |
| CA2454048C (en) * | 2001-07-17 | 2011-05-03 | Research Development Foundation | Therapeutic agents comprising pro-apoptotic proteins |
| JP4689268B2 (ja) | 2002-06-14 | 2011-05-25 | ザ ガバメント オブ ザ ユナイテッド ステイツ オブ アメリカ アズ リプレゼンテッド バイ ザ セクレタリー オブ ザ デパートメント オブ ヘルス アンド ヒューマン サービシーズ | Ｉｌ−１３およびｎｋ−ｔ細胞に関する、結腸炎を処置および予防する方法 |
| US9809654B2 (en) * | 2002-09-27 | 2017-11-07 | Vaccinex, Inc. | Targeted CD1d molecules |
| AU2005280163B2 (en) * | 2004-08-27 | 2011-11-24 | Albert Einstein College Of Medicine, Inc. | Ceramide derivatives as modulators of immunity and autoimmunity |
| ES2378076T3 (es) * | 2004-11-02 | 2012-04-04 | The Board Of Trustees Of Leland Stanford Junior University | Métodos para la inhibición de células NKT |
| PE20071101A1 (es) * | 2005-08-31 | 2007-12-21 | Amgen Inc | Polipeptidos y anticuerpos |
| WO2008140487A2 (en) | 2006-11-14 | 2008-11-20 | Elusys Therapeutics, Inc. | Improved staphylococcal protein a mono- and bispecific antibodies and methods of their use |
| WO2008100912A1 (en) * | 2007-02-12 | 2008-08-21 | The General Hospital Corporation | Methods for attenuating allergen-induced airway hyperreactivity using cd1d dependent antagonists |
| US8012484B2 (en) | 2007-04-12 | 2011-09-06 | University Of Virginia Patent Foundation | Method of treating ischemia reperfusion injury by inhibiting NKT cell activity |
| US20090028849A1 (en) * | 2007-07-24 | 2009-01-29 | O'brien Rebecca L | Agents and methods for inhibition of airway hyperresponsiveness |
| WO2009026412A1 (en) | 2007-08-21 | 2009-02-26 | Children's Medical Center Corporation | Treatment of airway hyperreactivity |
| EP2222700A2 (en) | 2007-11-27 | 2010-09-01 | Medtronic, Inc. | Humanized anti-amyloid beta antibodies |
| GB0902916D0 (en) | 2009-02-20 | 2009-04-08 | Fusion Antibodies Ltd | Antibody therapy |
| CA2792754C (en) | 2010-03-12 | 2019-11-12 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | .beta.-mannosylceramide and stimulation of nkt cell anti-tumor immunity |
| WO2011149881A2 (en) | 2010-05-24 | 2011-12-01 | Children's Medical Center Corporation | Methods for the treatment and prevention of inflammatory diseases |
| WO2013079687A1 (en) | 2011-11-30 | 2013-06-06 | The Chancellor, Masters And Scholars Of The University Of Oxford | Inkt cell modulators and methods of using the same |
| WO2015069697A2 (en) | 2013-11-05 | 2015-05-14 | Nkt Therapeutics Inc. | Combination therapy |
| US20160022777A1 (en) | 2014-07-28 | 2016-01-28 | Nkt Therapeutics Inc. | Combination therapy with il-12 |
-
2012
- 2012-10-26 HK HK14113013.0A patent/HK1199405A1/xx unknown
- 2012-10-26 WO PCT/US2012/062124 patent/WO2013063395A1/en not_active Ceased
- 2012-10-26 KR KR1020147014125A patent/KR20140093964A/ko not_active Abandoned
- 2012-10-26 BR BR112014009962A patent/BR112014009962A2/pt not_active IP Right Cessation
- 2012-10-26 EP EP12843689.6A patent/EP2755688A4/en not_active Withdrawn
- 2012-10-26 CA CA2853719A patent/CA2853719A1/en not_active Abandoned
- 2012-10-26 SG SG11201401319XA patent/SG11201401319XA/en unknown
- 2012-10-26 US US13/661,386 patent/US9932402B2/en not_active Expired - Fee Related
- 2012-10-26 JP JP2014539044A patent/JP2015502340A/ja active Pending
- 2012-10-26 AU AU2012328588A patent/AU2012328588C1/en not_active Ceased
- 2012-10-26 RU RU2014120694/10A patent/RU2014120694A/ru not_active Application Discontinuation
- 2012-10-26 CN CN201280053174.3A patent/CN103945867B/zh not_active Expired - Fee Related
- 2012-10-26 HK HK15100381.0A patent/HK1199837A1/xx unknown
-
2014
- 2014-04-08 IL IL232017A patent/IL232017A0/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015502340A5 (enExample) | ||
| RU2014120694A (ru) | ГУМАНИЗИРОВАННЫЕ АНТИТЕЛА К iNKT | |
| IL274595B2 (en) | Antibodies specific to beta-tgf | |
| JP2014526898A5 (enExample) | ||
| JP2013538057A5 (enExample) | ||
| JP2015535828A5 (enExample) | ||
| JP2016509009A5 (enExample) | ||
| JP2018512138A5 (enExample) | ||
| JP2012525829A5 (enExample) | ||
| JP2017504577A5 (enExample) | ||
| HRP20230844T1 (hr) | Anti-cd3 antitijela, bispecifične molekule koje vežu antigen koji veže cd3 i cd20, i njihove upotrebe | |
| JP2012501669A5 (enExample) | ||
| RU2018112861A (ru) | Стабильные антитела, связывающиеся с несколькими антигенами | |
| JP2015511962A5 (enExample) | ||
| JP2014509510A5 (enExample) | ||
| TR201817932T4 (en) | ANTIBODIES THAT BIND STAPHYLOCOCCUS AUREUS ALPHA TOXIN SPECIFICALLY AND METHODS OF USE | |
| JP2012254092A5 (enExample) | ||
| RU2015136078A (ru) | Антитело против с5 и способ предупреждения и лечения обусловленных комплементом заболеваний | |
| JP2018515474A5 (enExample) | ||
| JP2017505125A5 (enExample) | ||
| RU2016100892A (ru) | Антитела против tweakr и их применение | |
| JP2018502060A5 (enExample) | ||
| JP2017531427A5 (enExample) | ||
| JP2018510617A5 (enExample) | ||
| WO2008137915A3 (en) | Anti-icos antibodies and their use in treatment of oncology, transplantation and autoimmune disease |